Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. [electronic resource]
Producer: 20090304Description: 1446-53 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor -- genetics
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Disease-Free Survival
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride
- Female
- Gene Dosage
- Germany
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization, Fluorescence
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mitogen-Activated Protein Kinases -- metabolism
- Mutation -- genetics
- Phosphorylation
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- therapeutic use
- Survival Rate
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.